All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-YF291 | Human anti-POLY T cell receptor (VB3), pCDTCR1 | Virus | VB3 | Human | FMYSDFHFI | HLA-A*02:01 | Lentiviral vector | |
TCR-YF292 | Mouse anti-POLY T cell receptor (), pCDTCR1 | Hepatitis C virus | Mouse | CINGVCWTV | HLA-A*02:01 | Lentiviral vector | ||
TCR-YF293 | Human anti-POLY T cell receptor (HAT-140pM), pCDTCR1 | Hepatitis C virus | HAT-140pM | Human | KLKSLGLNAV | HLA-A*02:01 | Lentiviral vector | |
TCR-YF294 | Human anti-POLY T cell receptor (HAT-2nM), pCDTCR1 | Hepatitis C virus | HAT-2nM | Human | KLKSLGLNAV | HLA-A*02:01 | Lentiviral vector | |
TCR-YF295 | Human anti-POLY T cell receptor (HAT-40pM), pCDTCR1 | Hepatitis C virus | HAT-40pM | Human | KLKSLGLNAV | HLA-A*02:01 | Lentiviral vector | |
TCR-YF296 | Human anti-POLY T cell receptor (AF2), pCDTCR1 | Hepatitis C virus | AF2 | Human | LLFNILGGWV | HLA-A*02:01 | Lentiviral vector | |
TCR-YF297 | Human anti-POLY T cell receptor (TF1), pCDTCR1 | Hepatitis C virus | TF1 | Human | LLFNILGGWV | HLA-A*02:01 | Lentiviral vector | |
TCR-YF298 | Human anti-POLY T cell receptor (UB3), pCDTCR1 | Hepatitis C virus | UB3 | Human | LLFNILGGWV | HLA-A*02:01 | Lentiviral vector | |
TCR-YF299 | Human anti-POLY T cell receptor (WC2), pCDTCR1 | Hepatitis C virus | WC2 | Human | LLFNILGGWV | HLA-A*02:01 | Lentiviral vector | |
TCR-YF309 | Human anti-POLY T cell receptor (TH3), pCDTCR1 | Hepatitis C virus | TH3 | Human | YLLPRRGPRL | HLA-A*02:01 | Lentiviral vector | |
TCR-YF310 | Human anti-POLY T cell receptor (WD1), pCDTCR1 | Hepatitis C virus | WD1 | Human | YLLPRRGPRL | HLA-A*02:01 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION